论文部分内容阅读
目的探讨宫颈鳞癌血清鳞状细胞癌抗原(SCCA)动态监测的临床价值。方法对经临床病理确诊的265例宫颈鳞癌患者治疗前后采用酶联免疫吸附法(ELISA)检测血清SCCA水平。结果血清SCCA对于宫颈鳞癌的敏感性为65.28%。宫颈鳞癌患者治疗前血清SCCA水平与临床分期(P<0.001)、组织分化(P<0.005)、肿瘤大小(P<0.001)及盆腔淋巴结转移(P<0.005)之间,差异有统计学意义。265例宫颈鳞癌患者治疗后血清SCCA水平均明显下降,与治疗前相比差异有统计学意义(P<0.001)。治疗后161例无复发患者与57例复发的宫颈鳞癌患者血清SCCA水平之间差异有统计学意义(P<0.001),有78.95%复发患者血清SCCA水平在复发前3个月升高。结论 SCCA是宫颈鳞癌较特异的肿瘤标志物,对于辅助诊断、临床分期、疗后随访、监测复发均具有较好的临床参考价值。
Objective To investigate the clinical value of dynamic monitoring of squamous cell carcinoma antigen (SCCA) in cervical squamous cell carcinoma. Methods Serum levels of SCCA were detected by enzyme-linked immunosorbent assay (ELISA) before and after treatment of 265 cases of cervical squamous cell carcinoma clinically and pathologically confirmed. Results The sensitivity of serum SCCA to cervical squamous cell carcinoma was 65.28%. There were significant differences in the serum levels of SCCA and clinical stage (P <0.001), tissue differentiation (P <0.005), tumor size (P <0.001) and pelvic lymph node metastasis . The serum levels of SCCA in 265 patients with cervical squamous cell carcinoma were significantly lower than those before treatment (P <0.001). The difference of serum SCCA level between 161 relapsed patients and 57 patients with recurrent cervical squamous cell carcinoma was statistically significant (P <0.001). Serum SCCA level in 78.95% of relapsed patients increased 3 months before relapse. Conclusion SCCA is a specific tumor marker of cervical squamous cell carcinoma, which has good clinical value for diagnosis, clinical stage, follow-up after treatment and monitoring recurrence.